A high crosslinking grade of hyaluronic acid found in a dermal filler causing adverse effects.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Keizers, Peter H JVanhee, Celine
van den Elzen, Eef M W
de Jong, Wim H
Venhuis, Bastiaan J
Hodemaekers, Hennie M
Schwillens, Paul
Lensen, Daan G W
Type
ArticleLanguage
en
Metadata
Show full item recordTitle
A high crosslinking grade of hyaluronic acid found in a dermal filler causing adverse effects.Published in
J Pharm Biomed Anal 2018; 159:173-8Publiekssamenvatting
Facial treatments with dermal fillers for medical or esthetic purposes occasionally give rise to adverse effects, ranging from temporary effects such as reddening of the skin, to long term effects such as hardening of tissue. There appears to be a relationship between the lifetime of the filler product and the risk for adverse effects. The lifetime of hyaluronic acid-based fillers is dependent on the presence and amount of crosslinking agents such as 1,4-butanediol diglycidyl ether (BDDE). It would therefore make sense to establish methodology to analyze the crosslinking grade of HA-based filler products on a routine basis. To this end, an analytical method was developed and validated to identify HA-BDDE-based fillers and to quantify their modification and crosslinking grade. The method was subsequently applied to products from the legal supply chain and the illegal market. It was found that the product Hyacorp H 1000, previously taken from the market, indeed contains a high modification grade and crosslinking grade, as was the assumed reason for the increased risk for adverse effects of this product. However, it was also shown that the Hyacorp products are highly unreliable in relation to their product composition in general. In this study, authentic products could not be distinguished from the illegal market products based on their modification and crosslinking grade.PMID
29990883ae974a485f413a2113503eed53cd6c53
10.1016/j.jpba.2018.06.066
Scopus Count
Collections
Related articles
- HA-based dermal filler: downstream process comparison, impurity quantitation by validated HPLC-MS analysis, and in vivo residence time study.
- Authors: Guarise C, Barbera C, Pavan M, Panfilo S, Beninatto R, Galesso D
- Issue date: 2019 Jul-Sep
- In vitro toxicity assessment of crosslinking agents used in hyaluronic acid dermal filler.
- Authors: Jeong CH, Kim DH, Yune JH, Kwon HC, Shin DM, Sohn H, Lee KH, Choi B, Kim ES, Kang JH, Kim EK, Han SG
- Issue date: 2021 Feb
- Hyaluronan dermal fillers via crosslinking with 1,4-butandiol diglycidyl ether: Exploitation of heterogeneous reaction conditions.
- Authors: La Gatta A, Papa A, Schiraldi C, De Rosa M
- Issue date: 2016 Jan
- Detection of a new reaction by-product in BDDE cross-linked autoclaved hyaluronic acid hydrogels by LC-MS analysis.
- Authors: Fidalgo J, Deglesne PA, Arroyo R, Sepúlveda L, Ranneva E, Deprez P
- Issue date: 2018
- New Directions in Aesthetic Medicine: A Novel and Hybrid Filler Based on Hyaluronic Acid and Lactose Modified Chitosan.
- Authors: Daminato E, Bianchini G, Causin V
- Issue date: 2022 May 23